Ovarian Cancer News Feed

FDA expands use of AstraZeneca/Merck ovarian cancer drug
FDA expands use of AstraZeneca/Merck ovarian cancer drug(Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.read more
Source: Reuters
Published on Thu, 17 Aug 2017 16:22:00 GMT
Many breast, ovarian cancer survivors should take this genetic test
Many breast, ovarian cancer survivors should take this genetic testMore than 1 million American women who have had breast or ovarian cancer are not getting a simple genetic test that will determine whether they carry a mutation that puts them at higher risk of a recurrence, according to a UCLA study published Friday.read more
Source: 89.3 KPCC
Published on Sat, 19 Aug 2017 09:22:00 GMT
Resolution makes Sept. ‚ÄėOvarian Cancer Month‚Äô in Pa.
Resolution makes Sept. ‚ÄėOvarian Cancer Month‚Äô in Pa.With the help of Bradford woman Susan Evans, State Rep. Martin Causer, R-Turtlepoint, and other state legislators signed a resolution earlier in the summer that will officially designate September as ‚ÄúOvarian Cancer Month‚ÄĚ in Pennsylvania, with hopes ...read more
Source: Bradford Era
Published on Sat, 19 Aug 2017 07:10:00 GMT
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
Few women with history of breast cancer and ovarian cancer take a recommended genetic testOf the nearly 4 million women in the United States who have had either breast cancer or ovarian cancer, at least 1.5 million have a high risk of carrying certain types of genetic mutations that could increase their risk for additional cancers in the future.read more
Source: UCLA Newsroom
Published on Fri, 18 Aug 2017 13:15:00 GMT
Ovarian Cancer Market Still Up For Grabs
Ovarian Cancer Market Still Up For GrabsThe Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. While Lynparza, Rubraca (Clovis) and Zejula (Tesaro) have nuances in the efficacy and safety data ...read more
Source: barrons.com
Published on Sat, 19 Aug 2017 05:17:00 GMT
Walk/run to raise ovarian cancer awareness
Walk/run to raise ovarian cancer awarenessGOLDEN VALLEY, Minn. - September is Ovarian Cancer Awareness Month and the Minnesota Ovarian Cancer Alliance (MOCA) is leading the way in an effort to end ovarian cancer. The organization raises money for ovarian cancer research and has provided more than ...read more
Source: KARE 11
Published on Fri, 18 Aug 2017 16:40:00 GMT
Ovarian Cancer ‚Äď Opportunity Analysis and Forecasts to 2025
Ovarian Cancer ‚Äď Opportunity Analysis and Forecasts to 2025Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage ...read more
Source: Medgadget
Published on Fri, 18 Aug 2017 10:04:00 GMT
FDA Nod For PFE, New Use For AZN's Ovarian Cancer Drug, ELGX's LEOPARD Hits Goal
FDA Nod For PFE, New Use For AZN's Ovarian Cancer Drug, ELGX's LEOPARD Hits GoalToday's Daily Dose brings you news about expanded FDA approval of AstraZeneca's ovarian cancer drug Lynparza; positive results from Endologix's LEOPARD trial; Fluidigm's licensing agreement with Baylor Genetics; Humana and Amgen's partnership to improve ...read more
Source: Realtime Business News
Published on Thu, 17 Aug 2017 22:11:00 GMT
FDA Approvals in ALL, Ovarian Cancer, Priority Review in CTCL, and sNDA Submitted in RCC
FDA Approvals in ALL, Ovarian Cancer, Priority Review in CTCL, and sNDA Submitted in RCCFDA approvals in acute lymphoblastic leukemia and ovarian cancer, a priority review designation in cutaneous T-cell lymphoma, a supplemental new drug application in renal cell carcinoma, and results from a phase III kidney cancer trial. Welcome to OncLive ...read more
Source: OncLive
Published on Thu, 17 Aug 2017 08:00:00 GMT
Channel Nine's Clint Stanaway to ride 1000km to honour friend and raise money for fight against ovarian cancer
Channel Nine's Clint Stanaway to ride 1000km to honour friend and raise money for fight against ovarian cancerChannel Nine reporter Clint Stanaway will take part in the 'Silver Linings' ride from Adelaide to Melbourne to raise money for the fight against ovarian cancer. Bledisloe Cup: Wallabies great Michael Lynagh savages woeful Australia following loss to All ...read more
Source: wwos.nine.com.au
Published on Sat, 19 Aug 2017 16:55:00 GMT